Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
EUCR was delisted on the 26th of April, 2023.
5 hedge funds and large institutions have $2.98M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 34 closing their positions.
87% less funds holding
Funds holding: 38 → 5 (-33)
96% less capital invested
Capital invested by funds: $84.5M → $2.98M (-$81.6M)
97% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 34
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$219K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
-$10.2M |
| 2 |
DM
Deerfield Management
New York
|
-$10M |
| 3 |
BlackRock
New York
|
-$9.02M |
| 4 |
D.E. Shaw & Co
New York
|
-$6.68M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$6.53M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Millennium Management
New York
| – | -$802K | -80,000 | Closed |
|
|
CF
27
Cantor Fitzgerald
New York
| – | -$741K | -74,000 | Closed |
|
|
MC
28
Meteora Capital
Boca Raton,
Florida
| – | -$562K | -56,076 | Closed |
|
|
CIM
29
Cowen Investment Management
New York
| – | -$501K | -50,000 | Closed |
|
30
Goldman Sachs
New York
| – | -$307K | -30,622 | Closed |
|
31
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$225K | -22,427 | Closed |
|
|
MSU
32
Mizuho Securities USA
New York
| – | -$192K | -19,136 | Closed |
|
|
RL
33
RPO LLC
Stamford,
Connecticut
| – | -$191K | -19,012 | Closed |
|
|
LCM
34
Landscape Capital Management
Englewood,
New Jersey
| – | -$129K | -12,888 | Closed |
|
35
Morgan Stanley
New York
| – | -$39K | -3,900 | Closed |
|
|
WCMNY
36
Westchester Capital Management (New York)
Valhalla,
New York
| – | -$11K | -1,100 | Closed |
|
|
EC
37
Elequin Capital
New York
| – | -$5K | -500 | Closed |
|
|
AI
38
Arena Investors
Purchase,
New York
| – | -$1.8K | -180 | Closed |
|
EUCR Hedge Fund Activity: Q4 2022 in Review
5 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q4 2022, worth a combined $2.98M — down 96% from $84.5M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of EUCR and 1 opened new positions — a net loss of 33 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $219K. The largest seller was Glazer Capital LLC, exiting entirely with an estimated $10.2M sold.
- 5 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q4 2022, down from 38 in Q3 2022.
- Funds reported $2.98M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q4 2022, down 96% quarter-over-quarter.
- 1 fund opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q4 2022 and 34 closed out, a net change of -33 holders.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares buyer in Q4 2022 was Deutsche Bank, an estimated $219K added.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q4 2022 was Glazer Capital LLC, an estimated $10.2M sold.
Based on aggregated 13F filings for Q4 2022.